 |
GC Biopharma |
[Alpha Biz= Reporter Kim Sangjin] GC Biopharma reported a decline in its operating profit for the second quarter of the year. According to a disclosure on the 5th, the company's consolidated revenue for Q2 was 417.4 billion won, a 3.6% decrease compared to the same period last year. Operating profit fell by 25.5% year-on-year to 17.6 billion won, and the company recorded a net loss of 9.1 billion won, marking a shift to a deficit.
For the first half of the year (January to June), GC Biopharma's revenue was 774.2 billion won, down 1% from the previous year, and operating profit plummeted by 73.9% to 2.6 billion won. The company reported a net loss of 39.7 billion won.
The company attributed the revenue decline in Q2 to adjustments in the volume of blood products (immunoglobulin) being sold in different countries in preparation for the launch of its product "ALYGLO" in the U.S.
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
